239 related articles for article (PubMed ID: 32606733)
41. Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Gerhardt K; Jentzsch M; Georgi T; Sretenović A; Cross M; Bach E; Monecke A; Leiblein S; Hoffmann S; Todorović M; Bila J; Sabri O; Schwind S; Franke GN; Platzbecker U; Vučinić V
Front Oncol; 2021; 11():737645. PubMed ID: 34604075
[TBL] [Abstract][Full Text] [Related]
42. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
[No Abstract] [Full Text] [Related]
43. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
44. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
45. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B; Chung E; Wellard C; Yoo E; Bennett R; Birks C; Johnston A; Cheah CY; Hamad N; Simpson J; Barraclough A; Ku M; Viiala N; Ratnasingam S; Armytage T; Cochrane T; Chong G; Lee D; Manos K; Keane C; Wallwork S; Opat S; Hawkes EA
EJHaem; 2024 Apr; 5(2):325-332. PubMed ID: 38633125
[TBL] [Abstract][Full Text] [Related]
46. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
Goparaju K; Caimi PF
Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
[TBL] [Abstract][Full Text] [Related]
47. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
Mei M; Thomas S; Chen R
BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
[TBL] [Abstract][Full Text] [Related]
48. Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Argnani L; Broccoli A; Pellegrini C; Fabbri A; Puccini B; Bruna R; Tisi MC; Masia F; Flenghi L; Nizzoli ME; Musso M; Salerno M; Scalzulli PR; Dessi' D; Ferrarini I; Pennese E; Lucchini E; Rossi FG; Minoia C; Gherlinzoni F; Musto P; Patti C; Stefoni V; Zinzani PL
Hemasphere; 2022 Dec; 6(12):e798. PubMed ID: 36398133
[TBL] [Abstract][Full Text] [Related]
49. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
50. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
51. [Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].
Kong FC; Yu M; Zhou YL; Wang SX; Li F
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):66-69. PubMed ID: 35231996
[No Abstract] [Full Text] [Related]
52. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
53. Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Samineni D; Ding H; Ma F; Shi R; Lu D; Miles D; Mao J; Li C; Jin J; Wright M; Girish S; Chen Y
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S120-S131. PubMed ID: 33205435
[TBL] [Abstract][Full Text] [Related]
54. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
[TBL] [Abstract][Full Text] [Related]
55. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
Seon BK; Okazaki M; Duzen J; Matsuno F; Goey AKL; Maguire O
Leuk Res; 2024 Jan; 136():107436. PubMed ID: 38232613
[TBL] [Abstract][Full Text] [Related]
56. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
Thuresson PO; Vander Velde N; Gupta P; Talbot J
Adv Ther; 2020 Dec; 37(12):4877-4893. PubMed ID: 33001384
[TBL] [Abstract][Full Text] [Related]
57. Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report.
Alanzi M; Abu-Tineh M; Szabados L; Sharaf Eldean MZ; Alatasi S; Taha RY; Elkourashy SA
Onco Targets Ther; 2023; 16():133-139. PubMed ID: 36852093
[TBL] [Abstract][Full Text] [Related]
58. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
59. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Smith SD; Lopedote P; Samara Y; Mei M; Herrera AF; Winter AM; Hill BT; Shadman M; Ujjani C; Lynch RC; Jacobson CA; Kim AI; Caimi P; Milano F; Gopal AK
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):170-175. PubMed ID: 33431309
[TBL] [Abstract][Full Text] [Related]
60. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
Siddiqi T; Thomas SH; Chen R
Pharmgenomics Pers Med; 2014; 7():79-85. PubMed ID: 24672256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]